A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM

The goal of this study is to evaluate the efficacy and safety of multi-mode ablation combined with systemic therapy including PD-1(programmed death receptor 1) inhibitor for colorectal cancer liver metastasis and furthermore to clarify its application value by comparing preoperative and postoperative immune indicators.

Trial Details

NCT ID
NCT06590259
Phase
PHASE2
Sponsor
Shanghai 6th People's Hospital
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Multi-mode tumor treatment system
  • Sintilimab+mFOLFOX6 or FOLFIRI+bevacizumab or cetuximab
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Age 18-75 years, gender not specified;
  • Pathologically or clinically confirmed colorectal cancer liver metastases, with liver lesions unsuitable for surgical resection or intolerance or r…
  • In the case of an unresectable primary tumor or recurrence, the absence of serious complications such as bleeding or obstruction;
  • Failure of first-line treatment, with disease progression or new liver metastases;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →